Background Although typical pulmonary carcinoids (TC) are generally associated with excellent long-term outcomes, a subset of patients develops recurrence after complete resection. Current risk stratification largely relies on tumour size and TNM stage, yet the prognostic determinants of recurrence remain poorly defined. We aimed to identify clinicopathological predictors of recurrence in a homogeneous cohort of resected typical pulmonary carcinoids. Methods We retrospectively analysed consecutive patients undergoing surgical resection for pathologically confirmed TC between 2016 and 2022 at a high-volume thoracic surgery centre. Recurrence-free survival was estimated using the Kaplan–Meier method, with deaths occurring without documented recurrence censored at the time of death. Univariable Cox regression identified factors associated with recurrence, and parsimonious multivariable models were constructed according to the number of events. Results Among 115 patients, 97 had complete follow-up; six recurred (6.2%) after a median follow-up of 60.9 months. Nodal positivity showed the strongest recurrence signal and remained associated with recurrence in a parsimonious model including tumour size HR 7.40 (95% CI 1.49–36.83; p = 0.014). Positive node count and lymph node ratio were associated with recurrence in exploratory analyses (both p < 0.001) but were not assessed for incremental value beyond pN. Tumour size, Ki-67, surgical approach, and extent of pulmonary resection did not reach statistical significance. Node-positive patients had worse recurrence-free survival (p = 0.002). Conclusions In this single-centre cohort of resected typical pulmonary carcinoids, pathological nodal involvement showed a stronger association with recurrence than tumour size. Given the limited number of recurrence events, these findings should be considered hypothesis-generating and require validation in larger multicentre cohorts before informing postoperative risk stratification or surveillance strategies.
Purpose Reirradiation has become an area of increasing clinical and scientific interest, particularly in neuro-oncology. This non-systematic review on central nervous system (CNS) tumors by the CNS focus group of the European Society for Radiotherapy and Oncology provides a pragmatic synthesis of the available evidence, excluding gliomas. We address key questions related to patient selection, fractionation, technical considerations, and treatment safety. Methods Relevant studies on the use of reirradiation for meningiomas, ependymomas, brain metastases, and pituitary neuroendocrine tumors, as well as on the management of radiation necrosis, have been reviewed and summarized. Results Reirradiation has been used with varying success in primary and secondary brain tumors. The appropriate use of reirradiation requires consideration of numerous factors, including, but not limited to, prior treatment courses, fractionation, dose to organs at risk, imaging findings, the volume of the recurrent tumor, and the interval since prior treatments. The vast majority of available studies are limited by their retrospective design, lack of standardization in reporting, and overall heterogeneity across cohorts and treatments. Conclusion Several reirradiation studies across different tumor entities suggest potential efficacy and safety in carefully selected patients. However, important limitations remain, underscoring the need for well-designed prospective studies with rigorous reporting in both primary and secondary brain tumors.
To provide a clinically oriented synthesis of the epidemiology, pathophysiology, and management of bronchiectasis in patients with inflammatory bowel disease (IBD), and to clarify the key mechanisms underlying this association. Emerging evidence suggests a non-random association between IBD and bronchiectasis, with prevalence estimates varying widely according to study design and diagnostic approach. Mechanistic insights support a role for gut–lung axis dysfunction, including loss of mucosal tolerance, microbial dysbiosis, and immune cell trafficking. Clinically, bronchiectasis in IBD appears heterogeneous and may occur independently of intestinal disease activity. The increasing use of biologic therapies further complicates management, particularly regarding infection risk. Bronchiectasis should be recognised as a relevant extra-intestinal manifestation of IBD with important implications for diagnosis and management. A pragmatic, multidisciplinary approach is required, and further research is needed to define optimal screening strategies and tailored therapeutic pathways. Bronchiectasis is a frequent but under-recognized extra-intestinal manifestation of IBD. Awareness of the gut–lung axis and early multidisciplinary management are essential to balance inflammation control, infection risk, and respiratory outcomes in the era of biologic therapies.
Well-differentiated neuroendocrine tumors, grade 3 (NETs G3) of the digestive system are high-grade neuroendocrine neoplasms characterized by well-differentiated neuroendocrine morphology and high proliferative activity. Their molecular identity and therapeutic vulnerabilities remain incompletely defined. We performed a transcriptomic analysis and a comprehensive genomic profiling of 40 cases, including 26 NETs G3, 8 NETs G1/G2, and 6 neuroendocrine carcinomas (NECs). Targeted sequencing assessed alterations at both the DNA and RNA level, and gene expression profiling was conducted using a targeted immune-oncology panel. NETs G3 retained recurrent alterations in chromatin-regulatory genes characteristic of well-differentiated tumors and largely lacked the consistent TP53 and RB1 inactivation typical of NECs. Transcriptomic and genomic analysis demonstrated separation of NECs from NETs, with NETs G3 partially overlapping with NETs G1/G2 supporting a model of molecular relatedness. However, when compared with NETs G1/G2, NETs G3 showed upregulation of extracellular matrix remodeling, metabolic reprogramming, and cytokine signaling pathways. NETs G3 were heterogeneous in terms of number of genomic alterations per case and involved genes. A distinctive genomic feature was the predominance of large-segment copy-number losses, frequently involving chromatin-regulatory regions on chromosomes X and 10. Potentially targetable alterations were detected in up to 25% of NETs G3. Analysis of immune microenvironment supported a poorly inflamed tumor status, with individual cases harboring microsatellite instability or enrichment in tumor-infiltrating lymphocytes potentially amenable to immunotherapy.
Background: Augmented reality (AR) has rapidly emerged as an important navigational technology in spine surgery, with growing interest in its potential to reduce dependence on fluoroscopy and mitigate radiation exposure for both patients and operating room staff. Methods: This systematic review examined current evidence on radiation-related outcomes of AR-assisted spine procedures. A PRISMA-guided search of PubMed, Embase, and Scopus identified twelve eligible studies, including randomized trials, prospective and retrospective clinical cohorts, and cadaveric or synthetic-model investigations. Results: Across the included studies, AR was consistently associated with reduced fluoroscopy use, with several studies demonstrating statistically significant reductions in exposure time compared with conventional fluoroscopy. Two clinical studies directly measured occupational radiation and reported substantially lower staff doses when AR-based navigation and optimized shielding strategies were employed. Patient radiation exposure was similarly decreased in most studies, particularly when AR was integrated with low-dose cone-beam CT protocols. Operative time findings were mixed, reflecting early learning curves and variability in AR systems, but accuracy remained high across platforms. Conclusion: Current evidence suggests that AR may reduce intraoperative radiation exposure without compromising workflow or surgical precision, available studies are limited by small sample sizes, heterogenous methodologies, and a paucity of direct staff-dosimetry data. Larger, high-quality multicenter studies are needed to clarify the magnitude of AR’s radiation-sparing benefits and to define its role in modern spine surgery.